Key Points
- Medpace VP Susan Burwig sold 20,000 shares on November 24 at an average price of $609.15 for total proceeds of $12,183,000, leaving her with 27,500 shares — a 42.11% reduction in her prior ownership; the sale was disclosed in an SEC Form 4.
- Medpace beat quarterly expectations with $3.86 EPS (vs. $3.50 est.) and $659.9M revenue (+23.7% YoY), set FY2025 guidance of about $14.60–$14.86 EPS, while the stock trades near $606 with a $17.09B market cap and a MarketBeat consensus rating of Hold (price target $487.18).
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) VP Susan Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Medpace Stock Down 0.9%
Medpace stock opened at $606.60 on Thursday. The company has a market capitalization of $17.09 billion, a P/E ratio of 42.42, a PEG ratio of 2.67 and a beta of 1.42. The stock's 50 day moving average is $556.49 and its 200 day moving average is $440.30. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the company earned $3.01 EPS. The company's quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on MEDP shares. Wall Street Zen upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research note on Saturday, October 25th. Jefferies Financial Group lifted their price target on Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research report on Tuesday, September 9th. Rothschild Redb downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an "outperform" rating in a research note on Friday, October 24th. Finally, Zacks Research upgraded shares of Medpace from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $487.18.
Read Our Latest Stock Analysis on MEDP
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quent Capital LLC purchased a new stake in Medpace during the 3rd quarter valued at about $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace in the third quarter worth $27,000. Quarry LP purchased a new stake in shares of Medpace during the third quarter worth approximately $35,000. Root Financial Partners LLC acquired a new stake in Medpace in the third quarter valued at $38,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
